CR9663A - Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen - Google Patents

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Info

Publication number
CR9663A
CR9663A CR9663A CR9663A CR9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A
Authority
CR
Costa Rica
Prior art keywords
processes
condensed
compositions containing
dihydropiridine
heterocicles
Prior art date
Application number
CR9663A
Other languages
English (en)
Inventor
Jacques Mauger
Anil Nair
Nina Ma
Kirsten Bjergarde
Bruno Filoche-Romme
Odile Angouillant-Boniface
Serge Mignani
Cecile Combeau
Jean-Christophe Carry
Francois Clerc
Herve Minoux
Laurent Schio
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CR9663A publication Critical patent/CR9663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. La invencion se refiere a heterociclos dihidropiridina-condensados sustituidos utiles para el tratamiento de enfermedad de cancer, especialmente para prevenir la division de celulas cancerigenas. Estos compuestos actuan como inhibidores de Aurora A y /o B quinasas.
CR9663A 2005-07-20 2008-01-15 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen CR9663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291558A EP1746097B1 (en) 2005-07-20 2005-07-20 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Publications (1)

Publication Number Publication Date
CR9663A true CR9663A (es) 2008-02-21

Family

ID=35510894

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9663A CR9663A (es) 2005-07-20 2008-01-15 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Country Status (37)

Country Link
US (1) US8163768B2 (es)
EP (2) EP1746097B1 (es)
JP (2) JP2009501778A (es)
KR (1) KR101286796B1 (es)
CN (1) CN101243087B (es)
AR (1) AR054845A1 (es)
AT (2) ATE455115T1 (es)
AU (1) AU2006273692B8 (es)
BR (1) BRPI0614002A2 (es)
CA (1) CA2615700C (es)
CR (1) CR9663A (es)
CY (1) CY1109964T1 (es)
DE (1) DE602005018911D1 (es)
DK (1) DK1746097T3 (es)
DO (1) DOP2006000175A (es)
EA (1) EA016815B1 (es)
EC (1) ECSP078062A (es)
ES (1) ES2339676T3 (es)
HN (1) HN2008000088A (es)
HR (1) HRP20100195T1 (es)
IL (1) IL188861A0 (es)
MA (1) MA29634B1 (es)
MX (1) MX2008000902A (es)
MY (1) MY148617A (es)
NO (1) NO20080831L (es)
NZ (1) NZ592766A (es)
PE (2) PE20070212A1 (es)
PL (1) PL1746097T3 (es)
PT (1) PT1746097E (es)
RS (1) RS51351B (es)
SI (1) SI1746097T1 (es)
TN (1) TNSN08020A1 (es)
TW (1) TWI386411B (es)
UA (1) UA98928C2 (es)
UY (1) UY29685A1 (es)
WO (1) WO2007012972A2 (es)
ZA (1) ZA200800542B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) * 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
MX2014013373A (es) 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
WO2013171639A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
LT2909204T (lt) * 2012-10-12 2019-05-10 The Broad Institute, Inc. Gsk3 inhibitoriai ir jų panaudojimo būdai
WO2016094688A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
WO2016176657A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
WO2017124087A1 (en) 2016-01-15 2017-07-20 Memorial Sloan-Kettering Cancer Center Anti-parasitic compounds and uses thereof
EP3416950A1 (en) 2016-02-16 2018-12-26 Massachusetts Institute of Technology Max binders as myc modulators and uses thereof
CN110958882B (zh) 2017-04-05 2023-08-29 布罗德研究所股份有限公司 作为糖原合酶激酶3(gsk3)抑制剂的三环化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508324A (ja) * 1997-12-13 2002-03-19 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼ阻害剤としてのピラゾロ［３，４−ｂ］ピリジンの使用
EP1242422A1 (en) 1999-11-19 2002-09-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
JP2003525939A (ja) 2000-03-03 2003-09-02 アボット・ラボラトリーズ 三環式ジヒドロピラゾロン及び三環式ジヒドロイソオキサゾロンカリウムチャンネル開放剤
EP1355909A2 (en) 2001-02-02 2003-10-29 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
FR2823854A1 (fr) 2001-04-18 2002-10-25 Centre Nat Rech Scient Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
RU2006100484A (ru) * 2003-06-13 2006-06-10 Центарис ГмбХ, Германи (DE) Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках

Also Published As

Publication number Publication date
HN2008000088A (es) 2011-05-31
DOP2006000175A (es) 2007-03-31
PE20100718A1 (es) 2010-10-20
IL188861A0 (en) 2008-04-13
TWI386411B (zh) 2013-02-21
PE20070212A1 (es) 2007-03-21
KR101286796B1 (ko) 2013-07-17
NO20080831L (no) 2008-04-03
TNSN08020A1 (en) 2009-07-14
CA2615700A1 (en) 2007-02-01
US20080261969A1 (en) 2008-10-23
AU2006273692B8 (en) 2012-12-13
AU2006273692A8 (en) 2012-12-13
MA29634B1 (fr) 2008-07-01
PL1746097T3 (pl) 2010-06-30
TW200740812A (en) 2007-11-01
WO2007012972A3 (en) 2007-04-05
PT1746097E (pt) 2010-04-15
DK1746097T3 (da) 2010-05-25
UY29685A1 (es) 2007-02-28
AU2006273692B2 (en) 2012-11-22
CN101243087A (zh) 2008-08-13
DE602005018911D1 (de) 2010-03-04
EP1910366A2 (en) 2008-04-16
EP1746097A1 (en) 2007-01-24
ATE521611T1 (de) 2011-09-15
KR20080026658A (ko) 2008-03-25
ES2339676T3 (es) 2010-05-24
EA200800374A1 (ru) 2008-08-29
UA98928C2 (ru) 2012-07-10
WO2007012972A2 (en) 2007-02-01
AU2006273692A1 (en) 2007-02-01
NZ592766A (en) 2012-12-21
MY148617A (en) 2013-05-15
EP1910366B1 (en) 2011-08-24
ZA200800542B (en) 2010-02-24
AR054845A1 (es) 2007-07-18
CY1109964T1 (el) 2014-09-10
RS51351B (en) 2011-02-28
CA2615700C (en) 2013-06-18
JP2009501778A (ja) 2009-01-22
SI1746097T1 (sl) 2010-05-31
HRP20100195T1 (hr) 2010-05-31
MX2008000902A (es) 2008-03-26
CN101243087B (zh) 2013-07-24
ECSP078062A (es) 2008-01-23
EP1746097B1 (en) 2010-01-13
BRPI0614002A2 (pt) 2011-03-01
EA016815B1 (ru) 2012-07-30
US8163768B2 (en) 2012-04-24
ATE455115T1 (de) 2010-01-15
JP2013063987A (ja) 2013-04-11

Similar Documents

Publication Publication Date Title
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
UY30748A1 (es) Compuesto0s novedosos
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
GT200900027A (es) Compuestos organicos
ATE479687T1 (de) Kinaseinhibitoren
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
GT201000061A (es) Derivados de uracilo o timina para el tratamiento de hepatitis c
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
CR10782A (es) Compuestos para inhibir la progresion mitotica
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
GT200700006A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
UY29794A1 (es) Compuestos de sulfonamida, procesos e intermediarios para su preparación, composiciones farmacéuticas que los contienen y aplicaciones